Cargando…
SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore
Background: We evaluated the post-booster (BNT162b2) antibody responses in Singapore. Methods: Participants (n = 43) were tested pre-booster and 20/30/60/90 days post-booster. Participants were boosted 120–240 days (mean 214 days) after their second dose and had no history or serologic evidence of p...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879250/ https://www.ncbi.nlm.nih.gov/pubmed/35214789 http://dx.doi.org/10.3390/vaccines10020331 |
_version_ | 1784658853970837504 |
---|---|
author | Lau, Chin Shern Phua, Soon Kieng Liang, Ya Li Oh, May Lin Helen Aw, Tar Choon |
author_facet | Lau, Chin Shern Phua, Soon Kieng Liang, Ya Li Oh, May Lin Helen Aw, Tar Choon |
author_sort | Lau, Chin Shern |
collection | PubMed |
description | Background: We evaluated the post-booster (BNT162b2) antibody responses in Singapore. Methods: Participants (n = 43) were tested pre-booster and 20/30/60/90 days post-booster. Participants were boosted 120–240 days (mean 214 days) after their second dose and had no history or serologic evidence of prior COVID-19 infection; all participants had undetectable SARS-CoV-2 nucleocapsid antibodies throughout the study. Total nucleocapsid and spike antibodies (S-Ab) were assessed on the Roche Elecsys e802 and neutralizing antibody (N-Ab) on the Snibe quantitative N-Ab assay. Results: Pre-booster median S-Ab/N-Ab titers were 829 BAU/mL/0.83 µg/mL; 2 participants were below manufacturer’s N-Ab cut-offs of 0.3 µg/mL (0.192 and 0.229). Both S-Ab and N-Ab titers peaked at 30 days post-booster (median S-Ab 25,220 BAU/mL and N-Ab 30.3 µg/mL) at 30–37× pre-booster median levels. These peak post-booster S-Ab/N-Ab titers were 11× (25,220 vs. 2235 BAU/mL) and 9× (30.3 vs. 3.52 µg/mL) higher than the previously reported peak post-second dose levels. Antibody titers declined to 12,315 BAU/mL (51% decrease) and 14.3 µg/mL (53% decrease) 90 days post-booster. Non-linear regression estimates for S-Ab/N-Ab half-lives were 44/58 days. At 180 days post-booster, S-Ab/N-Ab are estimated to be 2671 BAU/mL/4.83 µg/mL. Conclusions: Both S-Ab and N-Ab show a good response following post-booster vaccination, with half-lives that may provide a prolonged antibody response. |
format | Online Article Text |
id | pubmed-8879250 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88792502022-02-26 SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore Lau, Chin Shern Phua, Soon Kieng Liang, Ya Li Oh, May Lin Helen Aw, Tar Choon Vaccines (Basel) Article Background: We evaluated the post-booster (BNT162b2) antibody responses in Singapore. Methods: Participants (n = 43) were tested pre-booster and 20/30/60/90 days post-booster. Participants were boosted 120–240 days (mean 214 days) after their second dose and had no history or serologic evidence of prior COVID-19 infection; all participants had undetectable SARS-CoV-2 nucleocapsid antibodies throughout the study. Total nucleocapsid and spike antibodies (S-Ab) were assessed on the Roche Elecsys e802 and neutralizing antibody (N-Ab) on the Snibe quantitative N-Ab assay. Results: Pre-booster median S-Ab/N-Ab titers were 829 BAU/mL/0.83 µg/mL; 2 participants were below manufacturer’s N-Ab cut-offs of 0.3 µg/mL (0.192 and 0.229). Both S-Ab and N-Ab titers peaked at 30 days post-booster (median S-Ab 25,220 BAU/mL and N-Ab 30.3 µg/mL) at 30–37× pre-booster median levels. These peak post-booster S-Ab/N-Ab titers were 11× (25,220 vs. 2235 BAU/mL) and 9× (30.3 vs. 3.52 µg/mL) higher than the previously reported peak post-second dose levels. Antibody titers declined to 12,315 BAU/mL (51% decrease) and 14.3 µg/mL (53% decrease) 90 days post-booster. Non-linear regression estimates for S-Ab/N-Ab half-lives were 44/58 days. At 180 days post-booster, S-Ab/N-Ab are estimated to be 2671 BAU/mL/4.83 µg/mL. Conclusions: Both S-Ab and N-Ab show a good response following post-booster vaccination, with half-lives that may provide a prolonged antibody response. MDPI 2022-02-18 /pmc/articles/PMC8879250/ /pubmed/35214789 http://dx.doi.org/10.3390/vaccines10020331 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lau, Chin Shern Phua, Soon Kieng Liang, Ya Li Oh, May Lin Helen Aw, Tar Choon SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore |
title | SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore |
title_full | SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore |
title_fullStr | SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore |
title_full_unstemmed | SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore |
title_short | SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore |
title_sort | sars-cov-2 spike and neutralizing antibody kinetics 90 days after three doses of bnt162b2 mrna covid-19 vaccine in singapore |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879250/ https://www.ncbi.nlm.nih.gov/pubmed/35214789 http://dx.doi.org/10.3390/vaccines10020331 |
work_keys_str_mv | AT lauchinshern sarscov2spikeandneutralizingantibodykinetics90daysafterthreedosesofbnt162b2mrnacovid19vaccineinsingapore AT phuasoonkieng sarscov2spikeandneutralizingantibodykinetics90daysafterthreedosesofbnt162b2mrnacovid19vaccineinsingapore AT liangyali sarscov2spikeandneutralizingantibodykinetics90daysafterthreedosesofbnt162b2mrnacovid19vaccineinsingapore AT ohmaylinhelen sarscov2spikeandneutralizingantibodykinetics90daysafterthreedosesofbnt162b2mrnacovid19vaccineinsingapore AT awtarchoon sarscov2spikeandneutralizingantibodykinetics90daysafterthreedosesofbnt162b2mrnacovid19vaccineinsingapore |